Review of insurance claims shows how practice behavior changes after approval of durvalumab
Immunotherapy after high-dose chemotherapy leads to favorable outcomes in acute myeloid leukemia
10 September 2021Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment
10 September 2021Review of insurance claims shows how practice behavior changes after approval of durvalumab
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.
